Some leading U.S. obesity specialists say they expect Eli Lilly’s powerful weight-loss drug Zepbound will produce the same or similar heart benefits as Novo Nordisk’s popular Wegovy as they belong to the same class of medicines. The views of the five doctors, all senior physicians practicing obesity medicine at top universities and hospitals, indicate that Novo's drug is not likely to have a significant edge based on its heart benefits, even though it will be years before Lilly produces similar cardiovascular data. Both medicines are GLP-1 agonists, a class originally designed to treat type 2 diabetes.
Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
Eli Lilly (NYSE: LLY) is a top growth stock to own. Although Eli Lilly's payout doesn't look like anything to get excited about (it currently yields less than 1%), that's deceptively low. Over the years the pharmaceutical giant has also increased its dividend payments.